Form 8-K - Current report:
SEC Accession No. 0000950170-21-004607
Filing Date
2021-11-15
Accepted
2021-11-15 16:21:36
Documents
14
Period of Report
2021-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tern-20211115.htm   iXBRL 8-K 53222
2 EX-99.1 tern-ex99_1.htm EX-99.1 192031
3 GRAPHIC img52906712_0.jpg GRAPHIC 6889
  Complete submission text file 0000950170-21-004607.txt   392360

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tern-20211115_pre.xml EX-101.PRE 10839
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tern-20211115.xsd EX-101.SCH 2513
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tern-20211115_lab.xml EX-101.LAB 14720
7 EXTRACTED XBRL INSTANCE DOCUMENT tern-20211115_htm.xml XML 5125
Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Filer) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39926 | Film No.: 211411031
SIC: 2834 Pharmaceutical Preparations